Solar urticaria caused by visible light in a 33-year-old male refractory to treatment with omalizumab.

Photodermatol Photoimmunol Photomed

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Published: July 2020

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12545DOI Listing

Publication Analysis

Top Keywords

solar urticaria
4
urticaria caused
4
caused visible
4
visible light
4
light 33-year-old
4
33-year-old male
4
male refractory
4
refractory treatment
4
treatment omalizumab
4
solar
1

Similar Publications

New insights into chronic inducible urticaria.

Curr Allergy Asthma Rep

August 2024

Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10178, Berlin, Germany.

Article Synopsis
  • Chronic inducible urticaria (CIndU) is a difficult-to-manage condition marked by recurring hives and swelling, triggered by specific factors, and recent research has focused on understanding its causes and improving treatment options.
  • New methods for evaluating patient experiences have been developed, highlighting the significant impact CIndU has on quality of life and enabling better diagnosis through provocation tests for different subtypes.
  • Currently, second-generation non-sedating antihistamines are the primary recommended treatment, but they often fall short; however, off-label use of omalizumab shows promise, along with other emerging therapies being researched for future options.
View Article and Find Full Text PDF

Chronic Inducible Urticaria.

Immunol Allergy Clin North Am

August 2024

Department of Dermatology and Venerology, Kepler University Hospital, Urticaria Center of Excellence and Reference (UCARE), Linz, Austria; Center for medical research, Johannes Kepler University, Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:

Article Synopsis
  • * Diagnosis relies on patient history, trigger tests, and self-reported symptoms.
  • * Current treatments mirror those for chronic spontaneous urticaria but are largely off-label; new targeted therapies are in clinical trials due to the significant impact on patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study highlights the effectiveness of traditional therapeutic plasmapheresis (TPE) as a treatment for difficult cases of solar urticaria (SU) that don't respond to common medications.* -
  • A specific case involving a patient who underwent 42 TPE procedures over five years showed significant improvement in their condition, as indicated by increased resistance to UV light during testing after treatment.* -
  • The research also compares the outcomes of this case with previous studies on TPE for SU, showing that patients with positive intradermal tests generally benefited more from TPE, although some relapsed in a short time.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!